AlloVir/ALVR

$0.73

-2.95%
-
1D1W1MYTD1YMAX

About AlloVir

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes posoleucel, ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, posoleucel, is a multi- VST therapy targeting six viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), JC virus (JCV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

Ticker

ALVR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Hallal

Employees

106

Headquarters

Waltham, United States

AlloVir Metrics

BasicAdvanced
$85.32M
Market cap
-
P/E ratio
-$1.72
EPS
0.84
Beta
-
Dividend rate

What the Analysts think about AlloVir

Analyst Ratings

Majority rating from 5 analysts.
Sell

Price Targets

Average projection from 4 analysts.
36.99% upside
High $1.50
Low $0.50
$0.73
Current price
$1.00
Average price target

AlloVir Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-44.2M
-2.21%
Profit margin
0%
-

AlloVir Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.25%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.37
-$0.44
-$0.48
-$0.39
-
Expected
-$0.54
-$0.47
-$0.45
-$0.42
-$0.43
Surprise
-31.9%
-5.38%
6.67%
-6.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell AlloVir stock

Buy or sell AlloVir stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing